Pioneering proposal for a new framework to describe types of MS

Moving away from traditional clinical categories of MS may lead to better, and more personalised treatments for MS.

Winner of the 2021 Young Investigator Award

Dr Giacomo Boffa receives the 2021 Young Investigator Award on his project on using aHSCT in individuals with secondary progressive MS

First treatment for people with secondary progressive MS in Europe is approved

An important milestone for people with secondary progressive MS in Europe

What determines conversion to secondary progressive MS?

An international study helps clinicians identify people who are at high risk of developing secondary progressive MS at an earlier stage.

Cladribine approved in US for people with active secondary progressive MS

FDA approves cladribine for people with relapsing forms of MS and active secondary progressive MS

Treatment licensed in US for people with active secondary progressive MS

FDA approves the drug Siponimod, to treat people with active secondary progressive MS

Natalizumab treatment may preserve upper limb function in secondary progressive MS

Results from a trial of natalizumab in secondary progressive MS suggest anti-inflammatory treatments could slow disability accumulation, even after significant function has been lost.

Do anti-inflammatory drugs delay disability in secondary progressive MS? 

A new study recently published uses ‘real-world’ data to investigate the effects of disease modifying therapies on secondary progressive MS

Types of MS

MS comes in several forms, including clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS and primary progressive MS.